PressLIVE NURO - NeuroMetrix Inc. 510(k) for SENSUS™ Pain Therapy Device - Diabetic Nerve Pain
NeuroMetrix, Inc. (Nasdaq: NURO - News), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes reported today that it has filed a premarket notification, or 510(k), with the Food and Drug Administration (FDA) for its SENSUS Pain Therapy device. SENSUS is a non-invasive transcutaneous electrical nerve stimulator intended to be used in the symptomatic relief and management of chronic intractable pain, such as painful diabetic neuropathy. SENSUS employs the same sophisticated nerve stimulation technology as the Company's NC-stat® DPNCheck™ device, and includes advanced features that the Company believes may address the technical and clinical limitations of existing nerve stimulators. The device also includes technology to maximize patient compliance, which is one of the fundamental challenges with pain therapy.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น